Epidemiology and clinical outcomes of light‐chain amyloidosis in Sweden: A nationwide population‐based study
- 2 August 2023
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 111 (5) , 697-705
Abstract
Objectives: This study evaluated data from six Swedish national registries to fill current evidence gaps on the epidemiology, clinical burden, and overall survival (OS) associated with light‐chain (AL) amyloidosis.Methods: Patients newly diagnosed with AL amyloidosis were identified using six linked Swedish nationwide population‐based registers. For each case, individuals from the general population were selected and matched with a maximum ratio of 1:5 based on age, sex, calendar year, and county.Results: 846 patients newly diagnosed with AL amyloidosis and 4227 demographically matched individuals were identified. From 2011 to 2019, annual AL amyloidosis incidence increased from 10.5 to 15.1 cases per million. At baseline, patients with AL amyloidosis had a significantly higher disease burden including higher rates of cardiac and renal failure relative to the comparison group. Among patients with AL amyloidosis, 21.5% had incident heart failure and 17.1% had incident renal failure after initial diagnosis. Median OS for patients with AL amyloidosis was 56 months versus not reached in the matched general population comparison group.Conclusion: The incidence of newly diagnosed AL amyloidosis in Sweden increased over time with AL amyloidosis being associated with a higher risk of cardiac/renal failure and all‐cause mortality compared with the general population.Keywords
This publication has 28 references indexed in Scilit:
- Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early deathBlood, 2017
- Registers of the Swedish total population and their use in medical researchEuropean Journal of Epidemiology, 2016
- A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosisBlood, 2013
- Incidence and survival in non-hereditary amyloidosis in SwedenBMC Public Health, 2012
- AL AmyloidosisOrphanet Journal of Rare Diseases, 2012
- External review and validation of the Swedish national inpatient registerBMC Public Health, 2011
- The Nordic Countries as a Cohort for Pharmacoepidemiological ResearchBasic & Clinical Pharmacology & Toxicology, 2010
- Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in ALBlood, 2006
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987